A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy.

Antonio González-Martín,Floor J. Backes,Klaus H. Baumann,Dana M. Chase,Mathias Fehr,Robert L. Coleman,Gilles Freyer,Paul DiSilvestro,Ofer Lavie,Thomas J. Herzog,Domenica Lorusso,Kathleen N. Moore,Mansoor Raza Mirza,R. O'Cearbhaill,Ignace Vergote,Bhavana Pothuri,John Balser,Shefali Agarwal,Bradley J. Monk

A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy.

2016

Antonio González-Martín
Floor J. Backes
Klaus H. Baumann
Dana M. Chase
Mathias Fehr
Robert L. Coleman
Gilles Freyer
Paul DiSilvestro
Ofer Lavie
Thomas J. Herzog
Domenica Lorusso
Kathleen N. Moore
Mansoor Raza Mirza
R. O'Cearbhaill
Ignace Vergote
Bhavana Pothuri
John Balser
Shefali Agarwal
Bradley J. Monk

TPS5606Background: Niraparib is a highly selective PARP1/2 inhibitor that induces synthetic lethality in tumor cells with homologous recombination DNA repair deficiencies (HRD). Niraparib is admini...

Keywords:

Ovarian cancer
Front line
Cancer research
Physical therapy
Medicine
Chemotherapy
Synthetic lethality
PARP1
advanced ovarian cancer
in patient
highly selective
double blind
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations